12:00 AM
 | 
Jan 09, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 1/6 cls
Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) RBC Capital Markets Jason Kantor Other Market outperform -19% $13.97
Kantor reiterated his rating after Aveo reported that oral tivozanib met the primary endpoint of median progression-free survival vs. Nexavar sorafenib in the Phase III TIVO-1 trial to treat advanced renal cell carcinoma (RCC) (11.9 vs. 9.1 months) (see B12). Although the results are "positive," Kantor said, he believes the Street expected a PFS with tivozanib of at least 13 months. Aveo and partner Astellas Pharma Inc. (Tokyo:4503) plan to submit regulatory applications for tivozanib in the U.S. and EU this year. Tivozanib is an inhibitor of VEGF receptors 1, 2 and 3. Bayer AG (Xetra:BAY) and Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) market Nexavar.
BioMimetic Therapeutics Inc. (NASDAQ:BMTI) Wedbush Gregory Wade Downgrade

Read the full 878 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >